Virpax Pharmaceuticals, Inc. (Virpax), a preclinical-stage pharmaceutical company, has announced an offering of up to 1,886,792 shares of common stock, along with Series A-1 and Series A-2 Common Warrants to purchase additional shares. The company is also offering Pre-Funded Warrants to certain investors as an alternative to common stock, which would result in ownership exceeding 4.99% or 9.99% of outstanding shares post-offering. The event is planned with A.G.P./Alliance Global Partners acting as the sole Placement Agent on a reasonable best-efforts basis. The offering is expected to close within two business days following its commencement, with the exact date of the offering and the closing date yet to be determined. The proceeds from the offering are intended...Show More

Virpax Pharmaceuticals, Inc. (Virpax), a preclinical-stage pharmaceutical company, has announced an offering of up to 1,886,792 shares of common stock, along with Series A-1 and Series A-2 Common Warrants to purchase additional shares. The company is also offering Pre-Funded Warrants to certain investors as an alternative to common stock, which would result in ownership exceeding 4.99% or 9.99% of outstanding shares post-offering. The event is planned with A.G.P./Alliance Global Partners acting as the sole Placement Agent on a reasonable best-efforts basis. The offering is expected to close within two business days following its commencement, with the exact date of the offering and the closing date yet to be determined. The proceeds from the offering are intended to be used for working capital and other general corporate purposes, including a $2.5 million payment obligation to plaintiffs as per a settlement agreement. The common stock is listed on the Nasdaq Capital Market under the symbol 'VRPX', while there are no plans to list the Pre-Funded Warrants or the Common Warrants on any securities exchange.